Comparative Pharmacology
Head-to-head clinical analysis: LICART versus SENSORCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LICART versus SENSORCAINE.
LICART vs SENSORCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Licart is a fibrin sealant containing human fibrinogen and thrombin. When applied, thrombin converts fibrinogen to fibrin, forming a stable clot that mimics the final stage of coagulation. It also contains factor XIII and aprotinin to cross-link fibrin and inhibit fibrinolysis, respectively.
SENSORCAINE (bupivacaine) is an amide-type local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting depolarization and propagation of action potentials, resulting in reversible local anesthesia.
Adults: 50 mg orally once daily.
Epidural or caudal block: 15-30 mL of 0.5% to 1% solution (75-150 mg) every 2-4 hours as needed. Maximum single dose: 225 mg.
None Documented
None Documented
Terminal elimination half-life of 6-8 hours in adults with normal renal function. Prolonged in renal impairment (up to 20-24 hours in ESRD), requiring dose adjustment in CrCl <30 mL/min.
The terminal elimination half-life of bupivacaine is approximately 2.7 hours in adults (range 1.5–5.5 hours). In neonates, the half-life is significantly prolonged (~8–12 hours) due to immature hepatic function, leading to an increased risk of toxicity.
Primarily renal excretion (80-85% as unchanged drug), with 10-15% biliary/fecal elimination. Less than 5% metabolized to inactive glucuronide conjugate.
SENSORCAINE (bupivacaine) is primarily metabolized in the liver via conjugation with glucuronic acid and undergoes hepatic dealkylation. Approximately 6% of the drug is excreted unchanged in the urine. The majority of the dose (about 95%) is excreted as metabolites in the urine (<10% unchanged) and the remainder in feces via biliary elimination.
Category C
Category C
Local Anesthetic
Local Anesthetic